Особенности ожирения и метаболических нарушений при синдроме Прадера-Вилли у детей

Цель исследования - анализ особенностей ожирения и "метаболического фенотипа" у детей с синдромом Прадере-Вилли (СПВ). Приведены результаты клинического и гормонально-метаболического обследования 45 препубертатных детей с генетически подтвержденным диагнозом СПВ (с ожирением и с нормальной массой тела) и контрольной группы из 47 больных с экзогенно-конституциональным ожирением. Несмотря на одинаковую степень ожирения процентное содержание жировой массы у пациентов с СПВ с ожирением было выше, чем у пациентов с экзогенно-конституциональным ожирением (р=0,01), а тощей - ниже (р<0,01). Встречаемость инсулинорезистентности среди детей с СПВ с ожирением составила 11,1%, что ниже, чем среди детей с экзогенно-конституциональным ожирением (42,5%) (p=0,013). Cодержание лептина в крови, встречаемость дислипидемий и процентное содержание жировой массы у детей с СПВ без ожирения были сходны таковыми у детей с экзогенно-конституциональным ожирением.

синдром Прадера-Вилли, ожирение, метаболический синдром, композиционный состав тела, инсулинорезистентность, гормон роста.

1. Emerick J.E., Vogt K.S. Endocrine manifestations and management of Prader-Willi syndrome. Int J Pediatr Endocrinol 2013; 1: 14, doi: 10.1186/1687-9856-2013-14.

2. Wattendorf D., Muenke M. Prader-Willi syndrome. Am Fam Phys 2005; 72: 5: 827-830.

3. Ho A.Y., Dimitropoulos A. Clinical management of behavioral characteristics of Prader-Willi syndrome. J Neurops Dis Treat 2010; 6: 107-118.

4. Yearwood E.L., McCulloch M.R., Tucker M.L., Riley J.B. Care of the patient with Prader-Willi syndrome. Medsurg Nursing. J Adult Health 2011; 20: 3: 113-122.

5. McCandless S.E., Cassidy S.B. Diagnostic criteria for Prader- Willi syndrome. In: Management of Prader-Willi syndrome. 3rd ed. Eds. M.G. Butler, P.D.K. Lee, B.Y. Whitman. New York: Springer 2006; 49-57.

6. Elena G., Bruna C., Benedetta M., Stefania D.C., Giuseppe C. Prader-Willi syndrome: clinical aspects. J Obes 2012; 2012: 473941. doi: 10.1155/2012/473941

7. Einfeld S.L., Kavanagh S.J., Smith A., Evans E.J., Tonge B.J., Taffe J. Mortality in Prader-Willi syndrome. Am J Ment Ret 2006;111:193-198.

8. Zipf W.B. Prader-Willi syndrome: the care and treatment of infants, children, and adults. Adv Pediatr 2004; 51: 409-434.

9. Lionti T., Reid S.M., Rowell M.M. Prader-Willi syndrome in Victoria: mortality and causes of death. J Paediatr Child Health 2012;48(6):506-511.

10. l’Allemand D., Eiholzer U., Schumpf M., Steinert H., Riesen W. Cardiovascular risk factors improve during 3 years of growth hormone therapy in Prader-Willi syndrome. Eur J Pediatr 2000;159:835-842.

11. Whittington J.E., Holland A.J., Webb T., Butler J., Clarke D., Boer H. Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK Health Region. J Med Genet 2001; 38: 792-798.

12. Obunai K., Jani S., Dangas G.D. Cardiovascular morbidity and mortality of the metabolic syndrome. Med Clin North Am 2007;91:1169-1184.

13. Cole T.J., Bellizzi M.C., Flegal K.M., Dietz W.H. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000; 320: 1240-1243.

14. Speiser P.W., Rudolf M.C., Anhalt H., Camacho-Hubner C., Chiarelli F., Eliakim A., et al. Childhood obesity. J Clin Endocrinol Metabol 2005; 90(3):1871-1887.

15. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114:555-576.

16. Kavey R.W., Simons-Morton D.G., de Jesus J.M. (ed.). Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. Pediatrics 2011; 128: Suppl: 5: 213-256.

17. Matsuda M., De Fronzo R.A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470.

18. Keskin M., Kurtoglu S., Kendirci M., Atabek M.E., Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents, Pediatrics 2005; 115(4):500-503.

19. Yeckel C.W., Weiss R., Dziura J., Taksali S.E., Dufour S., Burgert T.S., William V. Validation of insulin sensitivity indices from oral glucose tolerance test parameters in obese children and adolescents. J Clin Endocrinol Metabol 2004; 89: 1096-1101.

20. Weiss R., Bremer A.A.,Lustig R.H. What is metabolic syndrome, and why are children getting it? Ann N Y Acad Sci 2013; 1281(1):123-140.

21. Lee L., Arrington R. Sanders Metabolic Syndrome. Pediat Rev 2012;33:459-468.

22. Krochik A.G., Ozuna B., Torrado M., Chertkoff L., Mazza C. Characterization of alterations in carbohydrate metabolism in children with Prader-Willi syndrome. J Pediat Endocrinol Metabol 2006; 19(7):911-918.

23. Haqq A.M., Muehlbauer M.J., Newgard C.B., Grambow S., Freemark M. The metabolic phenotype of Prader-Willi syndrome (PWS) in childhood: heightened insulin sensitivity relative to body mass index. J Clin Endocrinol Metabol 2011; 96(1):225-232.

24. Tanaka Y., Abe Y., Oto Y., Itabashi H., Shiraishi M., Yoshino A., Obata K., Murakami N., Nagai T. Characterization of fat distribution in Prader-Willi syndrome: relationships with adipocytokines and influence of growth hormone treatment. Am J Med Genet A 2013; 161(1):27-33.

25. Lindgren A.C., Hagenäs L., Ritzén E.M. Growth Hormone Treatment of Children with Prader-Willi Syndrome: Effects on Glucose and Insulin Homeostasis. Horm Res 1999; 51(4):157-161.

26. Zipf W.B. Glucose homeostasis in Prader-Willi syndrome and potential implications of growth hormone therapy. Acta Paediatr 1999; 88(Suppl 433):115-117.

27. Crinò A., Di Giorgio G., Manco M., Grugni G., Maggioni A. Effects of growth hormone therapy on glucose metabolism and insulin sensitivity indices in prepubertal children with Prader-Willi syndrome. Horm Res 2007; 68(2): 83-90.

28. Brambilla P., Bosio L., Manzoni P., Pietrobelli A., Beccaria L., Chiumello G. Peculiar body composition in patients with Prader- Labhart-Willi syndrome. Am J Clin Nutrit 1997; 65: 1369-1374.

29. Theodoro M.F., Talebizadeh Z., Butler M.G. Body composition and fatness patterns in Prader-Willi syndrome: comparison with simple obesity. Obesity 2006; 14(10):1685-1690.

30. Eiholzer U., Blum W.F., Molinari L. Body fat determined by skin- fold measurements is elevated despite underweight in infants with Prader-Labhart-Willi syndrome. J Pediatr 1999; 134: 222-225.

31. Burman P., Ritzen E.M., Lindgren A.C.Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH. Endocrinol Rev 2001;22:787-799.

32. Thacker M.J., Hainline B., St Dennis-Feezle L., Johnson N.B., Pescovitz O.H. Growth failure in Prader-Willi syndrome is secondary to growth hormone deficiency. Horm Res 1998;49:216-220.

33. Corrias A., Bellone J., Beccaria L., Bosio L., Trifiro G., Livieri C., Ragusa L,. Salvatoni A., Andreo M., Ciampalini P., Tonini G., Crino A. GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology. J Endocrinol Invest 2000;23:84-89.

34. Grugni G., Guzzaloni G., Morabito F.Impairment of GH respon- siveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome. J Endocrinol Invest 2001;24:340-348.

35. Lindgren A.C., Ritzen E.M. Five years of growth hormone treat- ment in children with Prader-Willi syndrome. Swedish National Growth Hormone Advisory Group. Acta Paediat 1999;88(433 Suppl):109-111.

36. Carrel A.L., Myers S.E., Whitman B.Y., Allen D.B. Prader-Willi syndrome: the effect of growth hormone on childhood body com- position.Endocrinologist 2000; 10(4):3-49.

37. Eiholzer U., L’Allemand D., van der Sluis I.,Steinert H., Gasser T.,Kenneth E. Body composition abnormalities in children with Prader-Willi syndrome and long-term effects of growth hormone therapy. Horm Res 2000; 53: 200-206.

38. Myers S.E., Carrel A.L., Whitman B.Y., Allen D.B. Sustained ben- efi t after 2 years of growth hormone on body composition, fat uti- lization, physical strength and agility, and growth in Prader-Willi syndrome. J Pediatrics 2000; 137(1):42-49.

39. l’Allemand D., Eiholzer U., Schumpf M., Steinert H., Riesen W. Cardiovascular risk factors improve during 3 years of growth hormone therapy in Prader-Willi syndrome. Eur J Pediatr 2000; 159:835-842.

40. Lindgren A.C., Lindberg A. Growth Hormone Treatment Com- pletely Normalizes Adult Height and Improves Body Composi- tion in Prader-Willi Syndrome: Experience from KIGS (Pfizer International Growth Database). Horm Res 2008; 70: 182-187.

41. Carrel A.L., Myers S.E., Whitman B.Y., Eickhoff J., Allen D.B. Long-term growth hormone therapy changes the natural history of body composition and motor function in children with Prader-Willi syndrome. J Clin Endocrinol Metabol 2010; 95(3):1131-1136.

42. Ahima R.S., Saper C.B., Flier J.S., Elmquist J.K. Leptin regulation of neuroendocrine systems. Front Neuroendocrinol 2000; 21(3):263-307.

43. Patel S.B., Reams G.P., Spear R.M., Freeman R.H., Villarreal D. et al. Leptin: linking obesity, the metabolic syndrome, and cardio- vascular disease. Curr Hypertens Rep 2008;10(2):131-137.

44. Петеркова В.А., Косыгина А.В., Васюкова О.В. Адипонектин сыворотки крови при ожирении у детей и подростков. // Проблемы эндокринологии. - 2011. - Т. 57. - №6. - С. 9-14.